Dr. Michael Haichin has a longstanding fascination about substances that straddle the artificially constructed drug/medicine divide. This interest led him to pursue a B.Sc in Pharmacology from McGill University, followed by a PharmD from the University of Toronto. He aims to provide accurate and insightful information about psychedelics and has contributed as a Writer, Associate Editor, and Lead Editor for Psychedelic Science Review.
A deep dive into the strengths and limitations of the trial.
Was psilocybin really effective for treating depression?
Recent antidepressant exposure may reduce the treatment efficacy of MDMA.
Feasibility, safety, and potential efficacy of psilocybin-assisted group therapy was demonstrated in treating demoralization in this marginalized population.
Comments from Matthew Johnson of Johns Hopkins provide an update on this research.
Psychedelic Science Review is working to bring cutting-edge science in the field of psychedelics to the public in the most accessible, thorough and accurate way possible. Join our communities on Facebook, Twitter, LinkedIn and Instagram and share our content with your network to help us bring scientifically-backed information about psychedelics to the world.
NEW! Shop the PSR Supporter Store to show your support for psychedelic science.
